SG11202007873VA - Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor - Google Patents

Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Info

Publication number
SG11202007873VA
SG11202007873VA SG11202007873VA SG11202007873VA SG11202007873VA SG 11202007873V A SG11202007873V A SG 11202007873VA SG 11202007873V A SG11202007873V A SG 11202007873VA SG 11202007873V A SG11202007873V A SG 11202007873VA SG 11202007873V A SG11202007873V A SG 11202007873VA
Authority
SG
Singapore
Prior art keywords
cdk4
tumors
inhibitor
treatment
combination
Prior art date
Application number
SG11202007873VA
Other languages
English (en)
Inventor
Per Holm
Roman Nawroth
Original Assignee
Klinikum Rechts Der Isar Der Technischen Univ Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinikum Rechts Der Isar Der Technischen Univ Muenchen filed Critical Klinikum Rechts Der Isar Der Technischen Univ Muenchen
Publication of SG11202007873VA publication Critical patent/SG11202007873VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202007873VA 2018-03-05 2019-03-05 Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor SG11202007873VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18000210 2018-03-05
PCT/EP2019/000067 WO2019170283A1 (en) 2018-03-05 2019-03-05 Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Publications (1)

Publication Number Publication Date
SG11202007873VA true SG11202007873VA (en) 2020-09-29

Family

ID=61569019

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007873VA SG11202007873VA (en) 2018-03-05 2019-03-05 Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor

Country Status (13)

Country Link
US (1) US20210038661A1 (cg-RX-API-DMAC7.html)
EP (1) EP3762004B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021517119A (cg-RX-API-DMAC7.html)
KR (2) KR20210031852A (cg-RX-API-DMAC7.html)
CN (1) CN112533620B (cg-RX-API-DMAC7.html)
AU (1) AU2019232768B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092907A1 (cg-RX-API-DMAC7.html)
DK (1) DK3762004T3 (cg-RX-API-DMAC7.html)
ES (1) ES2965632T3 (cg-RX-API-DMAC7.html)
FI (1) FI3762004T3 (cg-RX-API-DMAC7.html)
HU (1) HUE064471T2 (cg-RX-API-DMAC7.html)
SG (1) SG11202007873VA (cg-RX-API-DMAC7.html)
WO (1) WO2019170283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021044061A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
EP4578943A4 (en) * 2022-08-25 2026-02-25 Fujifilm Corp PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
PL219321B1 (pl) * 2002-10-15 2015-04-30 Per Sonne Holm Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny
WO2005052143A2 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO2012022496A2 (en) * 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
US9271988B2 (en) * 2011-07-01 2016-03-01 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer
SG11201507393TA (en) * 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
AU2014272695B2 (en) * 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途

Also Published As

Publication number Publication date
WO2019170283A8 (en) 2019-11-07
CA3092907A1 (en) 2019-09-12
CN112533620A (zh) 2021-03-19
AU2019232768B2 (en) 2025-12-18
HUE064471T2 (hu) 2024-03-28
EP3762004B1 (en) 2023-09-13
EP3762004A1 (en) 2021-01-13
DK3762004T3 (da) 2023-11-27
AU2019232768A1 (en) 2020-09-03
CN112533620B (zh) 2025-03-28
US20210038661A1 (en) 2021-02-11
ES2965632T3 (es) 2024-04-16
KR20260089640A (ko) 2026-06-15
RU2020132466A (ru) 2022-04-05
JP2025013934A (ja) 2025-01-28
KR20210031852A (ko) 2021-03-23
RU2020132466A3 (cg-RX-API-DMAC7.html) 2022-04-05
WO2019170283A1 (en) 2019-09-12
FI3762004T3 (fi) 2023-12-11
JP2021517119A (ja) 2021-07-15

Similar Documents

Publication Publication Date Title
IL272948A (en) ENPP1 inhibitors and their use for cancer treatment
IL282727A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
IL276398B2 (en) Combination therapy for mastocytosis
IL276103A (en) Combined treatment with 70cd
SG10201913331VA (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
IL290011B1 (en) Ezh2 inhibition in combination therapies for cancer treatment
IL279260A (en) KDM1A inhibitors for the treatment of diseases
IL285221A (en) Use of oncolytic viruses to treat cancer
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
IL253521A0 (en) Combinations of a phosphoinositide 3-kinase inhibitor compound and a cdk4/6 inhibitor compound for cancer treatment
SG11202103141YA (en) Combination therapy for the treatment of cancer
HUE064471T2 (hu) Daganatok kezelése onkolitikus adenovírus és CDK4/6 inhibitor kombinációjával
BR112019003722A2 (pt) terapias de combinação para o tratamento de carcinoma hepatocelular
IL284225A (en) Combined treatment of solid tumors using docetaxel and a CYP3A inhibitor
IL284162A (en) Integrated healing for cancer treatment
IL281490A (en) Combinations of TGFB inhibitors and CDK inhibitors for the treatment of breast cancer
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201816547D0 (en) Oncolytic virus for the treatment of cancer
SG11202006874SA (en) Combination therapy for treating or preventing cancer
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
IL280262A (en) Compositions and methods for treating cancer
IL279000A (en) Treatment with AGI-134 together with a checkpoint inhibitor for the treatment of solid cancerous tumors
HUP1900281A1 (hu) Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra
HK40044035A (en) Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
GB201917701D0 (en) CD70 Combination therapy